BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 06, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Amigal migalastat HCl: Extension study data

Data from 23 patients enrolled in a Phase II extension study showed that Amigal was generally well tolerated with no drug-related serious adverse events. Patients who were responders at the completion of 4 Phase II trials continued to maintain elevated...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >